Atlas Trials

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Clinical trial NCT06536868 · RECRUITING

Trial details

NCT number
NCT06536868
Sponsor
Second Hospital of Shanxi Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Extensive-stage Small-cell Lung Cancer
Start date
2024-08-01
Primary completion
2026-12-31
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.